Nick DeVito

@ndevitomd.bsky.social

Assistant Prof, GI Oncologist @ Duke: immunotherapy, metastasis, and the immune microenvironment. TheDeVitoLab.org #FirstGen. USouthFlorida alum. Tufts residency survivor. Patients don’t fail treatments, treatments fail patients. Opinions=mine

My quote of the day I consider myself a perpetual student. You seek and learn every day: from an experiment in the lab, from reading a scientific journal, from taking care of a patient. Because of this, I rarely get bored. Anthony Fauci

A notable success in a disease where these have been rare. If your institution doesn’t have an EAP with RevMed started, now is the next best time to start working on one to ensure access to daraxonrasib for patients with pancreatic cancer. www.nejm.org/doi/full/10....

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, w...

nejm.org

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://nej.md/4nWaxvM #ASCO26

Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.

• Submit a comment opposing the destruction of 🇺🇸 science; • Pressure every org, professional body, association, uni, etc. you are affiliated with to submit the strongest possible comment opposing this calamity (highest ROI move for most of us) • Make sure your electeds see those comments 🧪

Trump's Russ Vought Is Trying To Kill American Science. We Can Try To Stop Him, | Shouldn't Need to Be a Lawyer by Matthew Cortland

Trump's Russ Vought Is Trying To Kill American Science. We Can Try To Stop Him, by Shouldn't Need to Be a Lawyer by Matthew Cortland on Patreon. Join Shouldn't Need to Be a Lawyer by Matthew Cortland...

patreon.com

tl,dr; Scientists no longer allowed to use federal funding to publish, attend meetings, or talk to the public. They cannot collaborate internationally. Grants can be cancelled for any reason, at any time, political appointees have a final say over what gets funded, and who gets funded.

Science Magazine@science.org · 2mo ago

The White House today announced it plans to make major changes in how the U.S. government manages research funding. https://scim.ag/43HgW4s

Once again: German universities were the envy of the world before the Nazis rose to power and took an ideological wrecking ball to the entire enterprise. If you want to know how long it took for German universities to recover… they haven’t.

Katie Mack@astrokatie.com · 2mo ago

It’s truly astonishing to see how comprehensively the US government is tearing down every part of the system that has made it up until now a world-leading power in science, research, and technological development. The entire world will suffer from this wanton destruction.

Scoop: NSF has been quietly blocking new funds and grants to four top universities: Duke, Harvard, Princeton, and Yale. Dozens of proposals from PIs at these universities—and their collaborators—have been stuck at the Office of Award Management awaiting finalization for months.

Exclusive: NSF puts new research grants to top universities on hold

US science funder once again restricts awards to Harvard University and other research institutions.

nature.com

5 𝐃𝐀𝐘𝐒 𝐋𝐄𝐅𝐓 ⏲️ Nominations for the 𝐘𝐯𝐨𝐧𝐧𝐞 𝐀𝐰𝐚𝐫𝐝𝐬 2026 officially close on 𝐀𝐩𝐫𝐢𝐥 1, 2026. More details🔗https://bit.ly/4dfzRtl Nominate now bit.ly/4uUMBfh #YvonneAwards2026 #OncoDaily #GlobalOncology #CancerLeadership #Innovation #PatientCare #ASCO2026

Yvonne Awards 2026

The Yvonne Awards, symbolizing the strength and longevity of the yew tree, honors exceptional achievements in oncology with its unique Y-shaped sculpture that

oncodaily.com